What are the fundraising trends in the synthetic biology market?
In our synthetic biology market deck, you will find everything you need to understand the market
SUMMARY
This report analyzes publicly disclosed equity rounds raised by pure-play synthetic biology companies between January 2024 and May 2026, with year-to-date comparisons through May 2026. We only kept disclosed rounds of $300K or more, excluded grants, debt, SPACs, acquisitions, undisclosed-size rounds, and non-pure-play companies, and used the month of announcement for timing.
The synthetic biology market expanded modestly in the last complete year. Disclosed capital rose from about $646M in 2024 to about $696M in 2025, while deal count increased from 19 to 28 including Geltor’s undisclosed round.
The fresher 2026 signal is weaker. From January through May 2026, the synthetic biology market raised about $238M across 13 deals, down from about $331M across 12 deals over the same period in 2025.
That means synthetic biology funding activity is being driven more by company formation than by larger rounds. The market is still printing deals, but the typical company is raising less than it did in prior windows.
Round sizes show the clearest reset. The median round fell from $20M in 2024 to $15M in 2025, then to $9.5M so far in 2026. The average round also fell to about $18.3M in early 2026, which confirms that large checks are less broadly available.
Capital remains concentrated at the top. In year-to-date 2026, the largest round, Think Bioscience at $55M, accounts for 23.1% of capital, while the top 3 deals account for 56.7% and the top 5 reach 78.8%.
Synthetic Biology Therapeutics leads year-to-date 2026 capital with $79M, or 33.2% of total dollars, from only 15.4% of deals. That makes therapeutics the most over-indexed category by check size.
Biofoundry Platforms and Synbio Food Platforms are nearly tied behind therapeutics, with about $65M each in year-to-date 2026 capital. Together, therapeutics, biofoundries, and food platforms captured almost 88% of early-2026 dollars.
Europe has taken the early-2026 regional lead, with 57.2% of capital and 61.5% of deals. North America remains essential, especially for therapeutics and materials, but its share is down from its dominant 2025 position.
The main interpretation is that the synthetic biology market is not collapsing; it is becoming more selective. Investors are still funding new companies, but they are reserving larger rounds for platforms with clinical relevance, manufacturing proof, regulatory progress, customer demand, or strategic participation.
This chart, featured in our synthetic biology market deck, illustrates the share of revenue generated by each customer segment in the synthetic biology market
Is more or less capital going into the synthetic biology market?
More capital went into the synthetic biology market in the last complete year, but less capital is going into the synthetic biology market so far in 2026 than over the same calendar period in 2025. Full-year disclosed capital rose from about $646M in 2024 to about $696M in 2025, an increase of roughly 8%, while January through May 2026 funding was about $238M, down from about $331M over the comparable 2025 period.
The more reliable structural read is that the synthetic biology market did not collapse after 2024. Deal count rose from 19 deals in 2024 to 28 deals in 2025 including Geltor’s undisclosed round, or 27 disclosed-size deals for capital metrics. That means the market broadened by company count even though investors became more selective about check size.
The fresher 2026 signal is weaker because the synthetic biology market has produced slightly more deals but materially less capital. So far in 2026, there were 13 deals versus 12 over the same period in 2025, but total capital was lower. The real signal is not fewer financings; it is smaller financings.
That matters because average round size fell from about $28M over the comparable early-2025 period to about $18M so far in 2026. Median round size fell from about $25M to $9.5M. The median is especially important because it tells us what a typical funded company is experiencing, not what the largest company can raise.
The best conclusion is that the synthetic biology market is moving from “more money for more companies” in 2025 to “selective money for fewer scale-worthy stories” in early 2026. The market is still investable, but the bar for large checks has risen.
Is synthetic biology funding driven by more deals or larger rounds?
Synthetic biology funding is currently being driven more by deal count than by larger rounds. The clearest evidence is that year-to-date 2026 has more deals than the comparable 2025 period, with 13 deals versus 12, but less capital, with about $238M versus about $331M.
The full-year comparison tells the same story in a cleaner way. Full-year capital rose only about 8% from 2024 to 2025, while deal count rose much faster, from 19 to 28 including Geltor. Average disclosed round size fell from about $34M in 2024 to about $26M in 2025.
The median round size is the most useful indicator here. It fell from $20M in 2024 to $15M in 2025, then to $9.5M so far in 2026. That progression shows that the typical synthetic biology company is raising less, even while the market continues to produce deals.
Concentration confirms the point. In 2024, the top 3 deals captured about 43% of capital. In 2025, the top 3 captured about 35%. So far in 2026, the top 3 captured about 57%, which means a few validated companies are still raising meaningful capital while most others are raising smaller seed or sub-$20M rounds.
For deeper benchmarks on synthetic biology deal sizes, median rounds, and round-distribution changes, see the synthetic biology market deck.
Is synthetic biology capital moving toward later-stage or earlier-stage companies?
Synthetic biology capital is not moving cleanly toward either later-stage or earlier-stage companies; it is moving toward validated companies. Those companies can sit at Series A, Series B, or Series C depending on the category, the proof points, and the capital intensity of the business.
In 2024, early-stage financings, defined as Seed, Series A, and Unknown, captured about $440M, or 68% of total capital. Late-stage Series B and Growth Equity captured about $206M, or 32%. By 2025, early-stage Seed plus Series A captured about $367M, or 53%, while Series B and later captured about $211M, or 30%, and Unknown or convertible-style rounds captured about $118M.
So far in 2026, the market is more balanced. Early-stage Seed plus Series A rounds captured about $122M, or 51% of capital. Later-stage Series B and above captured about $103M, or 43%. Unknown-stage rounds made up the remaining 5.7%.
Deal count tells a different story. Seed rounds are the most common stage so far in 2026, with 5 of 13 deals, yet seed rounds captured only 9.9% of dollars. The average seed round was under $5M and the median seed round was about $2.35M, which means new company formation is alive but usually capital-light.
Series A is currently the most important stage for serious capital formation. In 2025, Series A captured about 45% of disclosed capital. So far in 2026, Series A captured about 41%. The practical takeaway is that investors are using Series A as the test of whether a synthetic biology platform can move beyond novelty toward repeatability, customer relevance, manufacturing feasibility, or clinical path clarity.
This chart, featured in our synthetic biology market deck, compares the main business model options for synthetic biology platforms
Is the synthetic biology market maturing or still experimental?
The synthetic biology market is maturing, but it remains experimental beneath the surface. The most accurate read is a two-layer market: the top layer is maturing around therapeutics, biofoundry infrastructure, precision fermentation scale-up, and validated manufacturing platforms, while the lower layer remains experimental.
The maturity case is strongest in the full-year 2025 numbers. The market produced 28 deals, up from 19 in 2024, and total capital rose modestly to about $696M. More importantly, capital shifted toward categories where downstream validation is clearer.
Synthetic Biology Therapeutics captured about $293M in 2025, or 42% of disclosed capital, versus about $91M, or 14%, in 2024. Biofoundry Platforms also improved, from about $61M in 2024 to about $113M in 2025. These are not just scientific concepts; they are tied to clinical programs, cell programming, DNA synthesis, fermentation infrastructure, and manufacturing capacity.
The experimental layer is visible in deal size and stage mix. Median round size fell from $20M in 2024 to $15M in 2025 and then to $9.5M so far in 2026. Seed rounds remain common, but seed capital is small, which suggests investors are still buying technical options while reserving serious capital for more proven teams.
The best interpretation is that the synthetic biology market is maturing from a technology-promise market into a validation-screened market. The experimental layer has not gone away, and that is healthy. But the center of capital gravity has shifted toward companies that can show why engineered biology will work outside a lab.
Are new startups still entering the synthetic biology market?
Yes, new startups are still entering the synthetic biology market, but new entrants are being financed cautiously. First financings represented 38.5% of deals so far in 2026, up from 33.3% over the comparable period in 2025 and 31.6% in full-year 2024.
The caution is that first financings captured only 9.9% of capital so far in 2026. That compares with 22.4% over the comparable period in 2025 and 31.0% in full-year 2024. Startup formation is not drying up, but new startups are getting smaller checks.
This gap between first-financing deal share and first-financing capital share is the key interpretation. So far in 2026, 5 of 13 deals were first financings, but those deals raised only about $24M out of $238M. Investors are giving new companies enough capital to prove a technical, commercial, or platform milestone, not enough capital to assume scale-up success.
The categories of new entrants also matter. In 2026 so far, first financings appeared in Synbio Design Software, Engineered Microbes, Biofoundry Platforms, and Synbio Materials Platforms. Synthetic Biology Therapeutics and Synbio Food Platforms were entirely follow-on by deal count.
For the broader category view across synthetic biology startups, first financings, and subcategory formation, see the full synthetic biology market report.
Are more investors entering the synthetic biology market?
Investor participation in the synthetic biology market appears broad but not clearly expanding in a straight line. Full-year 2025 had approximately 80 disclosed named investors, roughly similar to 2024, while deal count rose substantially.
The freshest 2026 signal is that the market is still attracting many investors per deal. So far in 2026, there were approximately 72 disclosed investors across 13 deals. That suggests broad syndication and continued investor interest, although the current-year signal can be distorted by a few heavily syndicated rounds.
Tier-1 participation also looks stronger in early 2026 than the capital decline alone would suggest. The number of unique tier-1 investors is about 23 so far in 2026, compared with about 11 over the comparable period in 2025 and about 8 over the comparable period in 2024.
But the full-year comparison adds caution. Full-year 2025 disclosed approximately 80 named investors, about the same as 2024, despite a large increase in deal count. That means the market was not simply flooded with new capital providers. The same broad investor universe financed more companies with smaller average checks.
The better answer is that more credible investors are engaging selectively, rather than more investors flooding into synthetic biology indiscriminately. Strategic investors, life-science specialists, food and climate investors, and deeptech funds are still showing up, but they are showing up around specific theses.
This chart, featured in our synthetic biology market deck, illustrates yearly funding for synthetic biology startups
Are top investors getting more or less active in synthetic biology?
Top investors are getting more selective rather than simply more active in synthetic biology. The market has plenty of tier-1 and strategic participation, but repeat activity by the same top investors remains limited.
So far in 2026, only LocalGlobe and SOSV clearly appear in more than one qualifying deal, even though the first four months included 23 unique tier-1 investors. That means top investors are present, but most are making one targeted bet rather than building broad multi-deal exposure.
The full-year comparison shows the same pattern. In 2025, repeat investors included RA Capital, Eli Lilly, Khosla Ventures, ReGen Ventures, SOSV, and Main Sequence, each with 2 deals. That is more repeat activity than the early-2025 period, but it is still not a market dominated by a small group of hyperactive investors.
Top-investor activity is also shifting by category. In 2024, tier-1 conviction was highly visible in Synbio Design Software and AI-biology rounds, including Spark, Insight, Lux, AWS, NVIDIA, and Index-linked participation. In 2025, the strongest top-investor signal moved toward Synthetic Biology Therapeutics, with ARCH, TCGX, RA Capital, Third Rock, Lilly, Khosla, Johnson & Johnson Innovation, and DCVC Bio appearing in major rounds.
The important interpretation is that top investors are not abandoning the synthetic biology market. They are moving away from broad category enthusiasm and toward sharper category-specific underwriting. A top investor now needs to see a clinical or drug-discovery path, a manufacturing-cost or infrastructure advantage, or commercial demand from customers and strategics.
Which synthetic biology subcategories are gaining momentum?
The synthetic biology subcategories gaining momentum are Synthetic Biology Therapeutics, Biofoundry Platforms, and commercialization-led Synbio Food Platforms. These three categories together captured almost 88% of year-to-date 2026 capital.
Synthetic Biology Therapeutics is the clearest capital gainer. In 2024, therapeutics had 3 deals and about $91M. In 2025, the category had 6 deals and about $293M. So far in 2026, therapeutics has only 2 deals, but those 2 deals captured $79M, or 33% of capital.
The capital-share-to-deal-share ratio is especially important. Therapeutics has a ratio of 2.16 so far in 2026, the highest of any category. That means therapeutic synthetic biology is not just active; it is over-indexing on check size.
Biofoundry Platforms are also gaining momentum. Biofoundry capital rose from about $61M in 2024 to about $113M in 2025, and the category captured about $65M across 3 deals so far in 2026. bit.bio, Cauldron, and Fermeate show the category’s range: human cell programming, industrial biomanufacturing infrastructure, and fermentation control.
Synbio Food Platforms are gaining a more qualified form of momentum. Food had 11 deals in 2025, the highest deal count of any category, and 3 deals for about $65M so far in 2026. The nuance is that food momentum is not generic alt-protein enthusiasm; it is concentrated around ingredient-specific, scale-up-oriented companies such as Verley, Standing Ovation, and Clean Food Group.
We cover this subcategory shift in more detail in the deeper analysis of the synthetic biology market, including how therapeutics, biofoundries, food platforms, materials, microbes, and design software are moving in different directions.
Which synthetic biology subcategories are losing momentum?
Synbio Design Software is the clearest subcategory losing momentum from its 2024 peak, while Engineered Microbes and Synbio Materials Platforms remain active but undercapitalized. The full-year numbers are stark: Synbio Design Software captured about $257M in 2024, or 40% of capital, but only about $52M in 2025, or 8%.
So far in 2026, Synbio Design Software has only 1 deal and $9.5M, or 4% of capital. That does not mean AI for biology stopped mattering. It means the 2024 category was inflated by unusually large AI-biology rounds, especially EvolutionaryScale’s $142M seed and Cradle’s $73M round.
Engineered Microbes is losing momentum by capital share, not by company formation. The category captured about $156M in 2024, about $20M in 2025, and about $10M so far in 2026. Deal count has not vanished, but check size has compressed.
Synbio Materials Platforms are also weak by capital share. The category had about $24M in 2024, about $22M in disclosed-size capital in 2025 excluding Geltor’s undisclosed amount, and about $10M so far in 2026. Materials companies continue to appear, but large equity rounds remain rare.
The cleanest conclusion is that software-only and organism-engineering stories have become harder to finance at large scale unless they are attached to a more concrete endpoint. The synthetic biology market is not rejecting design, microbes, or materials. It is demanding stronger proof that those platforms convert into clinical value, manufacturing advantage, customer demand, or cost-down milestones.
This chart, featured in our synthetic biology market deck, shows how Twist Bioscience is capturing share in synthetic biology
Which regions are gaining momentum in synthetic biology funding?
Europe is gaining the most momentum in synthetic biology funding so far in 2026, while North America was the clear winner in full-year 2025. The freshest comparison is striking: Europe captured about 57% of capital and 62% of deals so far in 2026, versus about 30% of capital and 33% of deals over the comparable period in 2025.
The full-year comparison tells a different but useful story. In 2024, Europe had more deals than North America, with 10 deals versus 8, but North America raised slightly more capital, about $331M versus about $300M. In 2025, North America pulled far ahead, with about $500M, or 72% of disclosed capital, and 48% of deals.
So far in 2026, Europe has regained leadership. European financings include bit.bio, Biographica, Anzen Industries, Twogee Biotech, Verley, baCta, Standing Ovation, and Clean Food Group. This is not just a count effect. Europe supplied a $50M Series C, a $30M food-platform equity round, and a $28.5M Series B, along with multiple seed and early-stage financings.
Asia-Pacific is gaining a small but meaningful signal through Cauldron’s $13.25M round. The region had 1 deal in 2024, 3 disclosed-size deals in 2025, and 1 deal so far in 2026. That is not enough to claim a broad breakout, but the nature of the 2026 deal matters because Cauldron is a biomanufacturing infrastructure company.
The best answer is that Europe is the region gaining the most current momentum, North America remains the deepest capital pool on a full-year basis, and Asia-Pacific is present but still too thinly represented to call a broad regional acceleration.
Which regions are losing momentum in synthetic biology funding?
North America is losing momentum in early 2026 relative to its dominant 2025 position, while the Middle East and Africa have lost visible presence so far in 2026 after small but notable 2025 activity. The important nuance is that North America is not weak in absolute terms.
North America still captured about $89M so far in 2026. But its capital share fell from about 59% over the comparable early-2025 period to about 37% so far in 2026, and from about 72% in full-year 2025 to 37% so far in 2026.
The decline is mostly a relative shift caused by Europe’s strong start. North America still produced Think Bioscience, Antheia, Rubi, and Fermeate. Think Bioscience alone raised $55M, the largest disclosed round so far in 2026.
The Middle East had visible 2025 activity through Aleph Farms and Asterix Foods, with about $33M across 2 deals. So far in 2026, the Middle East has no qualifying disclosed deal in the January through May period. Africa also has no qualifying disclosed 2026 deal so far, after Immobazyme’s small 2025 financing.
Latin America remains absent across 2024, 2025, and early 2026 in the qualified deal record. Given Latin America’s agricultural and biomass advantages, that absence suggests financing infrastructure, venture density, and company-formation pathways matter more than feedstock relevance alone.
Is synthetic biology becoming more global or regionally concentrated?
The synthetic biology market became more global in 2025, but it is becoming more regionally concentrated again so far in 2026. The full-year 2025 record included North America, Europe, Asia-Pacific, the Middle East, and Africa, while 2024 was essentially North America, Europe, and one Asia-Pacific deal.
The full-year 2025 global expansion was real. North America led with about 72% of capital, Europe contributed about 20%, Asia-Pacific contributed about 3%, the Middle East contributed about 5%, and Africa appeared with a small but symbolically important financing.
The early-2026 picture is narrower. Europe has about 57% of capital and 62% of deals. North America has about 37% of capital and 31% of deals. Asia-Pacific has 1 deal and about 6% of capital. No other region appears.
The interpretation is that the synthetic biology market is globalizing at the edge but remains regionally concentrated at the core. Companies can emerge outside North America and Europe, and 2025 proved that. But large, source-verifiable equity rounds still cluster in regions with deep venture markets, technical universities, biomanufacturing infrastructure, strategic corporate partners, and regulatory pathways.
For ongoing regional tracking across Europe, North America, Asia-Pacific, the Middle East, Africa, and Latin America, see the market report covering synthetic biology geography.
This chart, featured in our synthetic biology market deck, shows how DNA tool adoption has driven growth in the synthetic biology market over time
Is synthetic biology capital moving toward proven winners or new opportunities?
Synthetic biology capital is moving toward proven winners for scale financing, while small checks are still being used to explore new opportunities. So far in 2026, first financings are 38.5% of deals but only 9.9% of capital, while follow-on financings dominate the capital pool.
The early-2026 category split reinforces the point. Synthetic Biology Therapeutics had no first financings so far in 2026 but captured 33% of total capital through Think Bioscience and Antheia, both follow-on rounds. Synbio Food Platforms also had no first financings but captured 27% of capital through Verley, Standing Ovation, and Clean Food Group, all follow-on rounds.
The full-year 2025 pattern was more balanced but still validation-led. First financings represented one-third of disclosed-size deals and 37% of capital, helped by large launches such as Stylus Medicine and Azalea Therapeutics. Those were technically first disclosed financings, but they came with major investors, strong therapeutic framing, and platform-grade ambition.
Top-deal concentration also points toward proven winners. So far in 2026, the top 3 deals captured about 57% of capital, and the top 5 captured about 79%. The bottom half of deals captured only about 12%.
The best answer is that the synthetic biology market has not stopped experimenting, but it is no longer treating every experiment as a future category leader. Serious capital is going to companies that already look more credible than the median deal.
Is the synthetic biology market becoming winner-takes-most?
The synthetic biology market is becoming winner-takes-most in capital allocation, but not winner-takes-all in company formation. The strongest current evidence is that so far in 2026, the top 3 deals captured about 57% of capital, the top 5 captured about 79%, and the bottom 6 deals captured only about 12%.
The full-year comparison adds nuance. In 2024, the top 3 deals captured about 43% of capital and the top 5 captured about 58%. In 2025, concentration softened by top-deal share: the top 3 captured about 35%, and the top 5 captured about 50%.
But the bottom half of deals still captured only about 12% of capital in 2025, down from about 16% in 2024. That means the middle and bottom of the synthetic biology market remained thinly capitalized even when top-deal concentration improved.
So far in 2026, concentration has intensified again. The largest deal, Think Bioscience’s $55M round, is 5.8x the median round. The market is not distorted by one massive $142M-style round like EvolutionaryScale in 2024. Instead, early 2026 is concentrated because the typical round is small and only a few companies can raise $30M to $55M.
The right conclusion is that the synthetic biology market is not yet winner-takes-all because category diversity remains high. But it is increasingly winner-takes-most because the capital needed to scale engineered biology is flowing to a small set of companies with the strongest validation.
Is the next wave of synthetic biology winners becoming visible?
Yes, the next wave of synthetic biology winners is becoming visible, but the visibility is uneven and should be treated as early evidence rather than final proof. The strongest candidates are not necessarily the newest companies; they are the companies that combine a platform, a concrete application, credible investors, and evidence of scale-up, clinical relevance, or customer demand.
So far in 2026, the most visible winner profiles are Think Bioscience, bit.bio, Verley, Standing Ovation, Antheia, Cauldron, and Rubi. Think Bioscience and Antheia show the therapeutic and pharmaceutical supply-chain path. bit.bio shows the human cell programming infrastructure path. Verley and Standing Ovation show the precision-fermentation ingredient path.
Cauldron shows the industrial biofoundry scale-up path. Rubi shows the materials path where offtake demand can matter as much as equity dollars. That last point matters because some synthetic biology categories may validate through customer commitments before they validate through large venture rounds.
The 2025 full-year comparison helps identify which kinds of winners are more likely to compound. Large 2025 rounds clustered around therapeutic platforms, food ingredient platforms, DNA synthesis, precision fermentation, and infrastructure. Examples included Arbor, Stylus, Azalea, Ansa, EVERY, Liberation Labs, Vivici, and Latent Labs.
The caution is that early-2026 capital is still thin. Total capital is down versus the comparable early-2025 period, median round size is much lower, and only 1 deal is strictly above $50M. The next wave is becoming visible, but synthetic biology winners usually need multiple rounds, regulatory progress, manufacturing proof, and customer adoption before the label is secure.
For more context on emerging synthetic biology winner profiles, see the full market view on synthetic biology winners.
As this chart shows, and as featured in our synthetic biology market deck, search interest in gene editing has grown significantly
Is the synthetic biology funding landscape fragmenting or consolidating?
The synthetic biology funding landscape is fragmenting by category and investor type, while consolidating around a small number of validation criteria. That sounds contradictory, but it is the most accurate read of the current market.
The deal record shows many submarkets: therapeutics, food, materials, engineered microbes, biofoundries, and design software. Each has different investors, round sizes, milestones, and risk models. But across those submarkets, investors are converging on the same question: does the company have proof that engineered biology can create a scalable advantage?
The fragmentation is visible in category rotation. In 2024, Synbio Design Software dominated capital with about 40% of dollars. In 2025, Synthetic Biology Therapeutics dominated with about 42%. So far in 2026, capital is split more evenly across therapeutics, biofoundries, and food platforms, each with roughly 27% to 33% of dollars.
Investor composition is also fragmented. Therapeutics rounds attract life-science investors, pharma strategics, and institutional healthcare capital. Food rounds attract foodtech funds, climate investors, dairy strategics, and ingredient companies. Biofoundry and manufacturing rounds attract deeptech investors, industrial strategics, and infrastructure-oriented capital.
But consolidation is visible in capital concentration. So far in 2026, the top 5 deals captured about 79% of capital. In 2025, the top 5 captured about 50%. The strongest conclusion is that the synthetic biology market is fragmenting as a taxonomy and consolidating as a financing market.
Where is investor attention shifting in synthetic biology?
Investor attention in the synthetic biology market is shifting toward validated applications of programmable biology: therapeutics, biofoundry infrastructure, fermentation scale-up, and commercialization-led food ingredients. The shift is away from broad platform storytelling and toward companies that can show a specific reason engineered biology will win.
The biggest full-year shift from 2024 to 2025 was from Synbio Design Software to Synthetic Biology Therapeutics. In 2024, design software captured about $257M, or 40% of capital. In 2025, design software dropped to about $52M, or 8%, while therapeutics rose to about $293M, or 42%.
This is not a rejection of AI. It is a shift from AI as a standalone financing story to AI and engineered biology as part of a more concrete therapeutic or manufacturing thesis.
So far in 2026, investor attention is more balanced. Therapeutics captured about $79M, Biofoundry Platforms captured about $65M, and Synbio Food Platforms captured about $65M. Together, those three categories captured almost 88% of early-2026 capital.
The sharpest conclusion is that investor attention is shifting from “can synthetic biology do something novel?” to “can synthetic biology do something economically repeatable?” The synthetic biology market is increasingly rewarding proof of translation, not just proof of invention.
All the funding deals in the synthetic biology market from 2024 to April 2026
The table below lists every disclosed funding round in the supplied synthetic biology dataset from January 2024 to April 2026, covering companies across biofoundry platforms, engineered microbes, synbio design software, synbio food platforms, synbio materials platforms, and synthetic biology therapeutics.
Each row shows the company, the fundraising date, what the company does, its category, the funding stage, the round size, the region, whether it was a first financing or a follow-on, the tier-1 investor if any, and the announcement source. For the broader investability view, see our longevity market deck.
| Company | Date | What they do | Category | Stage | Deal size | Region | First/Follow-on | Tier 1 investor(s) | Source |
|---|---|---|---|---|---|---|---|---|---|
| Fermeate | Apr 2026 | Optogenetic control platform for industrial precision fermentation, using light to control gene expression and improve productivity. | Biofoundry Platforms | Seed | $2M | North America | First financing | SOSV; Ajinomoto Group Ventures; Plug & Play | Business Wire |
| Clean Food Group | Apr 2026 | Yeast-derived oils and fats using proprietary fermentation technology and scalable yeast strains for food, cosmetics, and pet nutrition. | Synbio Food Platforms | Unknown | $6.1M | Europe | Follow-on | Clean Growth Fund; Döhler Group | Business Wire |
| Standing Ovation | Mar 2026 | Precision-fermented casein proteins for animal-free dairy applications. | Synbio Food Platforms | Series B | $28.5M | Europe | Follow-on | Bpifrance; Danone Ventures; Bel Group; Astanor; Seventure Partners | AgFunderNews |
| Cauldron | Mar 2026 | Continuous “hyper-fermentation” biofoundry and manufacturing platform for industrial-scale bioproduction using engineered microbes. | Biofoundry Platforms | Series A | $13.25M | Asia-Pacific | Follow-on | Main Sequence Ventures; SOSV; Horizons Ventures | Cauldron |
| Rubi | Mar 2026 | Cell-free, multi-enzyme CO2-to-materials platform for textile and industrial materials. | Synbio Materials Platforms | Unknown | $7.5M | North America | Follow-on | AP Ventures; H&M Group; Talis Capital | PR Newswire |
| baCta | Mar 2026 | Programmable microbial factories and biofoundry/AI strain-engineering platform for industrial ingredients. | Engineered Microbes | Seed | $7.6M | Europe | First financing | LocalGlobe | Tech.eu |
| Verley | Feb 2026 | Precision-fermented beta-lactoglobulin dairy proteins for food and nutrition applications. | Synbio Food Platforms | Series A | $30M | Europe | Follow-on | Sofinnova Partners | AgFunderNews |
| Twogee Biotech | Jan 2026 | Enzyme and strain-engineering platform for converting biomass residual streams into second-generation raw materials. | Engineered Microbes | Seed | $2.35M | Europe | First financing | HTGF | HTGF |
| Antheia | Jan 2026 | Advanced biosynthesis platform producing high-value pharmaceutical ingredients through engineered biology. | Synthetic Biology Therapeutics | Series C | $24M | North America | Follow-on | ATHOS KG; America’s Frontier Fund; GHIC | Antheia |
| Think Bioscience | Jan 2026 | Synthetic-biology-enabled drug discovery platform using high-throughput functional surveys to uncover druggable footholds on difficult targets. | Synthetic Biology Therapeutics | Series A | $55M | North America | Follow-on | Regeneron Ventures; Innovation Endeavors; Janus Henderson Investors | PR Newswire |
| Anzen Industries | Jan 2026 | Cell-free enzyme reactor systems for producing high-value chemicals outside living cells. | Synbio Materials Platforms | Seed | $2.2M | Europe | First financing | LocalGlobe | Tech.eu |
| bit.bio | Jan 2026 | Scalable human cell programming platform and ioCells products for drug discovery, toxicology, and cell-based models. | Biofoundry Platforms | Series C | $50M | Europe | Follow-on | M&G Investments | bit.bio |
| Biographica | Jan 2026 | AI/ML platform for crop gene-editing target discovery and experimental validation. | Synbio Design Software | Seed | $9.5M | Europe | First financing | None clearly tier-1 by global synbio/life-science VC standard | AgFunderNews |
| Mosa Meat | Dec 2025 | Develops cultivated beef using bovine cell culture and serum-free processes. | Synbio Food Platforms | Unknown | $16.5M | Europe | Follow-on | None identifiable from disclosed source | Protein Production Technology |
| All G | Dec 2025 | Produces lactoferrin and milk proteins through precision fermentation. | Synbio Food Platforms | Unknown | $6.6M | Asia-Pacific | Follow-on | Agronomics; Döhler Ventures | AgFunderNews |
| Melt&Marble | Dec 2025 | Produces designer fats using precision fermentation. | Synbio Food Platforms | Series A | $8M | Europe | Follow-on | Industrifonden; EIC Fund; Beiersdorf; Valio | Melt&Marble |
| Aether Biomachines | Dec 2025 | Turns AI-designed proteins into industrial and material solutions. | Synbio Materials Platforms | Unknown | $15M | North America | Follow-on | Tribe Capital; Henkel Corporation | Yahoo Finance |
| Immobazyme | Dec 2025 | Produces biologics, enzymes, growth factors, and therapeutic inputs via precision fermentation. | Engineered Microbes | Series A | $1.45M | Africa | Follow-on | None identified | Immobazyme |
| Erg Bio | Nov 2025 | Converts agricultural and forestry waste into intermediates for synthetic aviation fuels and bio-based chemicals. | Engineered Microbes | Seed | $6.5M | North America | First financing | Azolla Ventures; Chevron Technology Ventures | Erg Bio |
| Number 8 Bio | Nov 2025 | Develops biology-based livestock methane-reduction products. | Synbio Food Platforms | Series A | $7.18M | Asia-Pacific | Follow-on | Main Sequence | Startup Daily |
| Azalea Therapeutics | Nov 2025 | Engineers therapeutic cells directly inside patients using cell-specific delivery and programmable gene insertion. | Synthetic Biology Therapeutics | Series A | $82M | North America | First financing | Third Rock Ventures; RA Capital Management | GlobeNewswire |
| The EVERY Company | Nov 2025 | Produces egg proteins through precision fermentation. | Synbio Food Platforms | Series D+ | $55M | North America | Follow-on | McWin Capital Partners; Main Sequence; SOSV | The EVERY Company |
| Nutropy | Oct 2025 | Produces animal-free casein proteins using precision fermentation. | Synbio Food Platforms | Seed | $8.1M | Europe | Follow-on | Zero Carbon Capital; Novax | Green Queen |
| Asterix Foods | Oct 2025 | Uses plant cell culture to produce high-value bioactive proteins as an alternative to precision fermentation. | Synbio Food Platforms | Seed | $4.2M | Middle East | First financing | SOSV | Business Wire |
| Ansa Biotechnologies | Oct 2025 | Provides enzymatic DNA synthesis for synthetic DNA access. | Biofoundry Platforms | Series B | $54.4M | North America | Follow-on | Cerberus Ventures | Ansa Biotechnologies |
| Geltor | Aug 2025 | Produces animal-free collagen and bioactive proteins using precision fermentation and AI-enabled biodesign. | Synbio Materials Platforms | Unknown | Undisclosed | North America | Follow-on | Starlight Ventures | Geltor |
| Stylus Medicine | May 2025 | Develops precision in vivo genetic medicines using therapeutic-grade recombinases and LNP delivery. | Synthetic Biology Therapeutics | Series A | $85M | North America | First financing | RA Capital Management; Khosla Ventures; Eli Lilly and Company; Johnson & Johnson Innovation – JJDC | Stylus Medicine |
| Trilobio | May 2025 | Builds a robotic lab-in-a-box for automated biology experiments. | Biofoundry Platforms | Seed | $8M | North America | First financing | Initialized Capital; Lowercarbon Capital | Trilobio |
| Solena Materials | May 2025 | Uses AI and engineered microbes to design and produce protein-based fibers. | Synbio Materials Platforms | Seed | $6.7M | Europe | Follow-on | SynBioVen; Insempra | Solena Materials |
| Synthetic Design Lab | Apr 2025 | Develops SYNTHBODY next-generation antibody-drug conjugates based on protein engineering. | Synthetic Biology Therapeutics | Seed | $20M | North America | First financing | Playground Global | Business Wire |
| Grove Biopharma | Apr 2025 | Develops Bionic Biologics, a synthetic-biology-based therapeutic modality for intracellular targets. | Synthetic Biology Therapeutics | Series A | $30M | North America | Follow-on | DCVC Bio; Eli Lilly and Company | Business Wire |
| INTAKE | Apr 2025 | Uses yeast-based precision fermentation to produce alternative proteins. | Synbio Food Platforms | Series C | $9.2M | Asia-Pacific | Follow-on | CJ Investment; KDB Industrial Bank Capital | Vegconomist |
| Differential Bio | Mar 2025 | Builds an AI, microbiology, and lab-automation platform to de-risk bioprocess scale-up. | Synbio Design Software | Seed | $2.2M | Europe | First financing | None identified | AgFunderNews |
| Aleph Farms | Mar 2025 | Develops cultivated beef using cell-culture biomanufacturing. | Synbio Food Platforms | Unknown | $29M | Middle East | Follow-on | None identifiable from disclosed source | AgFunderNews |
| Arbor Biotechnologies | Mar 2025 | Develops CRISPR and reverse-transcriptase-based gene-editing therapeutics. | Synthetic Biology Therapeutics | Series C | $73.9M | North America | Follow-on | ARCH Venture Partners; TCGX | Arbor Biotechnologies |
| Vivici | Feb 2025 | Produces dairy proteins via precision fermentation for food ingredients. | Synbio Food Platforms | Series A | $33.7M | Europe | Follow-on | APG / ABP; Invest-NL; dsm-firmenich; Fonterra | Vivici |
| Oobli | Feb 2025 | Produces sweet proteins through precision fermentation for sugar reduction. | Synbio Food Platforms | Series B | $18M | North America | Follow-on | Khosla Ventures | Oobli |
| Latent Labs | Feb 2025 | Builds AI foundation models for programmable biology, protein and enzyme design. | Synbio Design Software | Series A | $50M | Europe | First financing | Radical Ventures; Sofinnova Partners; 8VC | Latent Labs |
| Enduro Genetics | Feb 2025 | Engineers microbes with genetic circuits that stabilize high production in biomanufacturing. | Engineered Microbes | Series A | $12.4M | Europe | Follow-on | None identified | Enduro Genetics |
| Liberation Labs | Jan 2025 | Builds large-scale precision fermentation manufacturing infrastructure. | Biofoundry Platforms | Unknown | $50.5M | North America | Follow-on | None identifiable from disclosed source | AgriNovus Indiana |
| Esphera SynBio | Jan 2025 | Develops engineered exosome-based synthetic biology nanomedicine vaccines for cancer and infectious disease. | Synthetic Biology Therapeutics | Seed | $2M | North America | First financing | None identified | PR Newswire |
| Cradle | Nov 2024 | AI platform and wet-lab infrastructure for protein design and engineering. | Synbio Design Software | Series B | $73M | Europe | Follow-on | Index Ventures if participating in 2024 round; otherwise not confirmed | TechCrunch |
| baCta | Oct 2024 | Uses AI and precision fermentation to turn microorganisms into programmable molecular factories, initially targeting biosynthetic natural rubber. | Synbio Materials Platforms | Seed | $3.6M | Europe | First financing | Kima Ventures | EU-Startups |
| Integrated Biosciences | Oct 2024 | Uses synthetic biology and machine learning to develop therapeutics for age-related diseases. | Synthetic Biology Therapeutics | Seed | $17.2M | North America | First financing | Sutter Hill Ventures; Illumina Ventures Labs | Business Wire |
| Constructive Bio | Sep 2024 | Engineers custom genomes and novel biomolecules using synthetic genomics; reprograms biology to create new-to-nature molecules. | Engineered Microbes | Series A | $58M | Europe | Follow-on | Not clearly disclosed | SynBioBeta |
| Abolis Biotechnologies | Sep 2024 | Industrial biomanufacturing company using microorganisms to make biobased equivalents and novel products. | Engineered Microbes | Growth Equity | $37.8M | Europe | Follow-on | L’Oréal/BOLD; Evonik Venture Capital | Abolis Biotechnologies |
| Switch Bioworks | Sep 2024 | Develops engineered microbes that produce sustainable nitrogen fertilizer. | Engineered Microbes | Seed | $17M | North America | First financing | Astanor Ventures; KdT Ventures; Acre Venture Partners | PR Newswire |
| Standing Ovation | Aug 2024 | Makes animal-free casein via precision fermentation. | Synbio Food Platforms | Series A | $4.1M | Europe | Follow-on | Astanor Ventures; Seventure; Bel Group | Edible Planet Ventures |
| Biomatter | Aug 2024 | Generative AI enzyme design platform for creating functional enzymes. | Synbio Design Software | Seed | $7M | Europe | First financing | None clearly tier-1 globally; UVC is recognized deep-tech investor | SynBioBeta |
| Again | Jul 2024 | Commercializes genetically engineered microbes that convert CO2 and hydrogen into acetic acid and derivatives. | Engineered Microbes | Series A | $43M | Europe | Follow-on | GV | Chemical & Engineering News |
| GRO Biosciences | Jul 2024 | Uses synthetic biology and genomically recoded organisms to make protein therapeutics incorporating non-standard amino acids. | Synthetic Biology Therapeutics | Series B | $60.3M | North America | Follow-on | Atlas Venture; Access Biotechnology; Leaps by Bayer | Business Wire |
| EvolutionaryScale | Jun 2024 | Builds AI models for protein design and biological research; launched ESM3 for reasoning across protein sequence, structure, and function. | Synbio Design Software | Seed | $142M | North America | First financing | Lux Capital; AWS; NVIDIA/NVentures | Gunderson Dettmer |
| Radar Therapeutics | May 2024 | Develops programmable medicines using molecular RNA sensors. | Synthetic Biology Therapeutics | Seed | $13.4M | North America | First financing | Eli Lilly and Company; KdT Ventures | Business Wire |
| Allozymes | May 2024 | Enzyme discovery and engineering platform using ultra-high-throughput screening to develop industrial enzymes. | Biofoundry Platforms | Series A | $15M | Asia-Pacific | Follow-on | SOSV; Seventure Partners | PR Newswire |
| Elegen | May 2024 | Next-generation DNA synthesis and production platform, expanding into clinical manufacturing. | Biofoundry Platforms | Series B | $35M | North America | Follow-on | a16z Bio + Health; GSK; 8VC | Elegen |
| SOLASTA Bio | Apr 2024 | Develops nature-inspired peptide bioinsecticides for agriculture. | Synbio Food Platforms | Series A | $13.6M | Europe | Follow-on | Forbion; Corteva Catalyst; FMC Ventures | BusinessCloud |
| Onego Bio | Apr 2024 | Produces animal-free egg protein via precision fermentation. | Synbio Food Platforms | Series A | $40M | Europe | Follow-on | NordicNinja; Tesi | Onego Bio |
| Profluent | Mar 2024 | AI-first protein design company using large biological models to design proteins and gene-editing systems. | Synbio Design Software | Unknown | $35M | North America | Follow-on | Spark Capital; Insight Partners | Silicon Valley Daily |
| Tierra Biosciences | Mar 2024 | AI-guided, cell-free, on-demand custom protein synthesis platform for high-throughput protein production. | Biofoundry Platforms | Series A | $11.4M | North America | Follow-on | Prosus Ventures; In-Q-Tel | Global AgInvesting |
| Insempra | Jan 2024 | Produces bio-based ingredients for food, beauty, personal care, nutrition, and materials using biotechnology and precision fermentation. | Synbio Materials Platforms | Series A | $20M | Europe | Follow-on | EQT Ventures | Green Queen |
INSIGHTS
The insights below come from reviewing disclosed equity rounds in the synthetic biology market across full-year 2024, full-year 2025, and January through May 2026.
- The synthetic biology market is no longer best understood as one single category. Therapeutics, food, biofoundry infrastructure, materials, engineered microbes, and design software now behave like separate financing markets with different round sizes, investor types, and proof requirements.
- The most important shift from 2024 to 2026 is not the change in total capital; it is the change in what earns large capital. In 2024, AI-biology design software could dominate the capital stack. By 2025 and early 2026, large checks increasingly required clinical, manufacturing, or commercialization proof.
- The synthetic biology market has become broader by deal count but narrower by serious capitalization. More companies are getting funded, yet the bottom half of deals consistently captures only a small share of total dollars.
- Median round size is the most useful health indicator in this market because average round size is repeatedly distorted by top deals. The fall from $20M in 2024 to $15M in 2025 to $9.5M so far in 2026 signals a tougher financing environment for the typical company.
- The decline in median round size does not mean the synthetic biology market is dying. It means investors are funding more companies with smaller proof-oriented rounds while reserving large checks for companies that already look validated.
- The synthetic biology market is increasingly milestone-priced. Companies with clinical paths, manufacturing infrastructure, regulatory progress, customer demand, or strategic participation can raise meaningful rounds. Companies with only technical novelty receive smaller option-sized financings.
- The category that looks strongest depends on the metric chosen. Food leads by deal count in 2025, therapeutics leads by capital in 2025, and biofoundry platforms become strategically important when the question is where bottleneck-solving infrastructure is emerging.
- Therapeutic synthetic biology has the clearest path to large checks because it can borrow the economics of biotech. Large markets, high-value assets, pharma validation, and familiar clinical milestones make therapeutic synbio structurally more financeable than many industrial or food applications.
- Food synthetic biology is active but not fully re-rated. The high deal count shows survival and continued investor interest, while lower median check sizes show that investors remain cautious about cost, scale-up, regulation, and consumer-market uncertainty.
- Precision fermentation has shifted from novelty financing to execution financing. Investors no longer appear to reward “animal-free protein” by itself; they reward specific ingredients, manufacturing progress, strategic partners, and market-entry evidence.
- Biofoundry platforms are gaining importance because they attack the industry’s shared bottleneck: translating biological design into repeatable production. This makes biofoundries closer to infrastructure than to single-product companies.
- The strongest synthetic biology companies increasingly look like bottleneck owners. The most credible platforms control something scarce: cell programming, DNA synthesis, fermentation control, high-value molecule production, clinical programmability, or customer-validated materials.
- Engineered Microbes is a formation-rich but capital-light category. Investors keep funding new organism-engineering companies, but the small check sizes imply skepticism about whether standalone microbe platforms can scale without clear customers or infrastructure advantages.
- Materials synthetic biology is not yet commanding large equity rounds, but it may be developing a different validation model. Rubi’s offtake term sheets suggest customer demand can become a substitute signal for large venture financing.
- The absence of $100M-plus rounds in 2025 and early 2026 is a major market reset. The synthetic biology market still supports $50M-scale rounds, but it has not returned to peak-era mega-round behavior.
- The largest early-2026 rounds cluster around companies that solve practical problems rather than companies that merely expand scientific possibility. Think Bioscience, bit.bio, Verley, Standing Ovation, and Antheia all fit specific commercial or clinical use cases.
- The synthetic biology market is becoming more rigorous because investors now distinguish between invention risk and translation risk. Many companies can show engineered biology works technically; fewer can show engineered biology works economically, clinically, or industrially.
- Europe’s strong early-2026 performance is not just a function of more small spinouts. Europe produced meaningful rounds across cell programming, food ingredients, and fermentation-adjacent platforms, which suggests deeper regional maturity than the 2025 capital split implied.
- North America remains the highest-conviction region for large therapeutic and platform rounds, even when its overall share falls. A decline in North American share should be read as Europe gaining strength, not as North America exiting the market.
- Asia-Pacific remains too thinly represented to infer broad acceleration, but the presence of Cauldron matters because it sits in infrastructure. One infrastructure deal is more strategically informative than one narrow end-product deal.
- Latin America’s continued absence is one of the clearest negative signals. Feedstock relevance and agricultural need do not automatically create synthetic biology financing without venture depth, technical company formation, and disclosure-rich funding ecosystems.
- The Middle East and Africa showed signs of participation in 2025 but have not yet established repeatability. Their current role is episodic rather than structurally embedded in the synthetic biology financing market.
This chart, featured in our synthetic biology market deck, shows how gene therapy technology has evolved over time
OUR METHODOLOGY TO BUILD THIS TRACKER
We built this synthetic biology funding tracker by reviewing publicly disclosed equity rounds raised by pure-play synthetic biology companies between January 2024 and May 2026. A company counts as pure-play when more than 80% of its activity is dedicated to engineering biological systems using designed DNA, genetic circuits, engineered organisms, synthetic-biology software, biofoundry or automation infrastructure, or synbio-enabled end products.
We applied four filters to build the dataset. First, we only included equity or equity-like financing rounds, so grants, debt-only financings, structured financings, SPAC transactions, acquisitions, and business combinations are excluded. Second, we only counted disclosed rounds of $300K or more. Third, we only kept pure-play synthetic biology companies, which means we excluded conventional biotech, pharma, fermentation, food, materials, or software companies where synthetic biology was not central to more than 80% of the business. And fourth, every entry had to be confirmed by a direct company announcement, press release, tier-1 media report, specialized industry source, or relevant regional publication.
For blended rounds, we counted only the equity component when the source separated equity from non-dilutive support. For example, Verley, Standing Ovation, and Clean Food Group were treated using equity-only amounts. We also kept disclosed-amount deals when the stage was Unknown, because excluding them would remove real capital formation from the market.
Undisclosed-amount rounds are excluded from dollar-based metrics because including them would distort averages, medians, category shares, and concentration ratios. Geltor’s 2025 undisclosed equity financing is therefore included in deal-count context where appropriate but excluded from capital, average round size, median round size, and deal-size bucket calculations.
The final dataset uses month-and-year announcement timing, disclosed deal size, company category, stage, geography, first-financing versus follow-on status, disclosed investors, and source-backed deal verification. Privately raised rounds that were never publicly announced are necessarily missing, which is a known limitation of any public-only synthetic biology funding tracker.
Related blog posts
- The latest changes in the synthetic biology market
- The most recent news in synthetic biology
- How large is the synthetic biology market today?
- The most recent funding news in synthetic biology
- The evolution of funding activity in synthetic biology
- The startups that have raised the most funding in synthetic biology
